NEW YORK, June 21, 2023 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Fulcrum Therapeutics, Inc.
Shareholders who purchased shares of FULC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
PERIOD CLASS: March 3, 2022 to March 8, 2023
ALLEGATIONS: The complaints alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
DEADLINE: June 27, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=41075&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of FULC during the timeframe listed above, you will be enrolled in a portfolio of monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 27, 2023. There is no cost or obligation for you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incur losses when false and/or misleading statements or the omission of material information by a company leads to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY10018
Email: [email protected]
Phone: (646) 453-8903
View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-fulcrum-therapeutics-inc-of-a-class-action- lawsuit-and-a-lead-plaintiff-deadline-of-june-27-2023–nasdaq-fulc-301856352.html
SOURCE The Gross Law Firm
